ArticleInternational journal of nanomedicine2015
Nanoencapsulation of pomegranate bioactive compounds for breast cancer chemoprevention.
Article in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 112 citations in OpenAlex.
- Pomegranate in Cancer Therapy: A Review of Anticancer Potential, Mechanisms and Clinical Challenges in Breast, Colon and Prostate Cancers.Phytotherapy research : PTR · 2026Review
- A novel approach to enhance beta-sitosterol bioavailability isolated fromFrontiers in oncology · 2025Article
- Bioactivity and biomedical applications of pomegranate peel extract: a comprehensive review.Frontiers in pharmacology · 2025Review
- Confocal Microscopy Investigations of Biopolymeric PLGA Nanoparticle Uptake inPlants (Basel, Switzerland) · 2023Article
- TRAIL mediated apoptosis ruling and anticancer trigger by fine-tuned nano spheres of Fagonia cretica methanolic extracts as novel cancer regime.Scientific reports · 2023Article
- A review of nanomaterials from synthetic and natural molecules for prospective breast cancer nanotherapy.Frontiers in pharmacology · 2023Review
- Enhanced Bioactivity of Pomegranate Peel Extract following Controlled Release from CaCOBioinorganic chemistry and applications · 2022Article
- Puerarin inhibits EMT induced by oxaliplatinFrontiers in pharmacology · 2022Article
- Ellagic Acid: A Review on Its Natural Sources, Chemical Stability, and Therapeutic Potential.Oxidative medicine and cellular longevity · 2022Review
- Nutraceuticals and Cancer: Potential for Natural Polyphenols.Nutrients · 2021Review
- Review
- Pharmacological and Therapeutic Properties ofMolecules (Basel, Switzerland) · 2021Review
- Immunomodulatory Role of Urolithin A on Metabolic Diseases.Biomedicines · 2021Review
- Pomegranate variety and pomegranate plant part, relevance from bioactive point of view: a review.Bioresources and bioprocessing · 2021Review
- Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature.International journal of nanomedicine · 2021Review
- Article
- Metabolic Activity of Anthocyanin Extracts Loaded into Non-ionic Niosomes in Diet-Induced Obese Mice.Pharmaceutical research · 2020Article
- Effect of microencapsulation on antioxidant and antifungal properties of aqueous extract of pomegranate peel.Journal of food science and technology · 2020Article
- Nanoformulated Bioactive Compounds Derived from Different Natural Products Combat Pancreatic Cancer Cell Proliferation.International journal of nanomedicine · 2020Article
- Cancer Chemoprevention Using Nanotechnology-Based Approaches.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pomegranate polyphenols are potent antioxidants and chemopreventive agents but have low bioavailability and a short half-life. For example, punicalagin (PU), the major polyphenol in pomegranates, is not absorbed in its intact form but is hydrolyzed to ellagic acid (EA) moieties and rapidly metabolized into short-lived metabolites of EA. We hypothesized that encapsulation of pomegranate polyphenols into biodegradable sustained release nanoparticles (NPs) may circumvent these limitations. We describe here the development, characterization, and bioactivity assessment of novel formulations of poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) (PLGA-PEG) NPs loaded with pomegranate extract (PE) or individual polyphenols such as PU or EA. Monodispersed, spherical 150-200 nm average diameter NPs were prepared by the double emulsion-solvent evaporation method. Uptake of Alexa Fluor-488-labeled NPs was evaluated in MCF-7 breast cancer cells over a 24-hour time course. Confocal fluorescent microscopy revealed that PLGA-PEG NPs were efficiently taken up, and the uptake reached the maximum at 24 hours. In addition, we examined the antiproliferative effects of PE-, PU-, and/or EA-loaded NPs in MCF-7 and Hs578T breast cancer cells. We found that PE, PU, and EA nanoprototypes had a 2- to 12-fold enhanced effect on cell growth inhibition compared to their free counterparts, while void NPs did not affect cell growth. PU-NPs were the most potent nanoprototype of pomegranates. Thus, PU may be the polyphenol of choice for further chemoprevention studies with pomegranate nanoprototypes. These data demonstrate that nanotechnology-enabled delivery of pomegranate polyphenols enhances their anticancer effects in breast cancer cells. Thus, pomegranate polyphenols are promising agents for nanochemoprevention of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.